Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to the U.S., if required, as ...

The weight loss drug market is booming, with GLP-1 medications projected to hit $100 billion by 2030. These drugs, which help ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Buying low to sell later when the stock's price is high is a time-honored investing strategy. With the benchmark S&P 500 ...

We recently published a list of 10 Best Affordable Dividend Stocks to Buy According to Hedge Funds. In this article, we are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best ...

Pfizer’s chief executive in Ireland has told the Government the system of giving patients access to new medicines has become ...

Indeed, the ambitious project — which involves a $27 billion investment — comes as pharmaceutical executives try to navigate ...

Pfizer's stock is trading at $25.89, and it ranks second among the best stocks under $50. Despite a rough selloff, the S&P ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Pfizer Inc. (NYSE:PFE) is a leading global pharmaceutical company that researches, manufactures, and markets prescription ...